Lupin Limited has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-3 facility in India. The report follows an inspection conducted between 7 and 17
Touchlight has announced the expansion of its mbDNA™ platform with three new circular DNA architectures—sscDNA, hsscDNA, and dscDNA—broadening its portfolio of cell-free DNA solutions for gene editing and expression. The new constructs complement the mbDNA technology introduced earlier this year,
Sandoz has signed a strategic agreement with Evotec SE to acquire all issued and outstanding equity interests of Just-Evotec Biologics EU SAS (JEB SAS), which includes its biomanufacturing site in Toulouse, France. The move supports the company’s long-term biosimilar growth
Argonaut Manufacturing Services, a contract development and manufacturing organisation (CDMO) specialising in aseptic drug product manufacturing and the production of life science and diagnostic products, has appointed Rick Hancock as Chief Executive Officer (CEO). Rick brings over 40 years of
SK Capital Partners, a New York-based private investment firm specialising in the life sciences, ingredients, and specialty materials sectors, has completed its previously announced acquisition of LISI Group’s Medical division. The business, now renamed Precera Medical, has established its headquarters
VIVOLTA, a specialist in electrospun medical implant manufacturing, has announced a long-term agreement for a dedicated production facility at High Tech Campus Eindhoven. The move represents a key milestone in the company’s expansion, driven by increasing customer demand for industrial-scale
Matica Biotechnology, Inc. has announced a strategic partnership with Calidi Biotherapeutics, Inc., a clinical-stage immuno-oncology company developing oncolytic virus-based therapies. The agreement covers analytical development, process development, and GMP manufacturing to support the IND submission for CLD-401, Calidi’s lead candidate
Ginkgo Bioworks has secured a contract worth up to $22.2 million through the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing
Samsung Biologics has announced the completion of its spin-off of Samsung Bioepis, finalising the establishment of Samsung Epis Holdings as part of its strategy to operate as a pure-play Contract Development and Manufacturing Organization (CDMO). The separation, approved by the
IntoCell Inc., a biotechnology company developing next-generation payload and linker technologies for antibody–drug conjugates (ADCs), has announced a strategic collaboration with Xcellon Biologics, a U.S.-based contract development and manufacturing organisation (CDMO) specialising in ADCs and complex biologics. Under the agreement,
